Psychedelic Stock Gainers And Losers From August 31, 2022
GAINERS:
Small Pharma (OTC:DMTTF) shares closed up 31.95% at $0.24
Nasdaq-listed Bright Minds Closes $4 Million Offering And Begins Dosing In Clinical Trial For Epilepsy
Biopharma company developing next-generation mental health treatments Bright Minds Biosciences Inc. (NASDAQ: DRUG) has closed its overnight offering for gross proceeds of approximately $4 million.
This Company Just Created 3 Brand New Psychedelics—Without The Hallucinogenic Side Effects
Mindset Pharma Inc. (OTCQB: MSSTF), a company producing psychedelic and non-psychedelic drugs for mental health conditions has recently identified three additional families of highly novel, non-tryptamine psychedelic compounds.
Where To Buy Legal Weed These Days: Cresco, TILT & Ayr Wellness Launch Cannabis Shops
Cresco Labs Expands Retail Footprint In Florida
Worried About A Drug Test Getting You Fired? California’s Got Your Back, As Long As You Aren’t High On The Job
A bill that would prevent employers from sanctioning their workers who use recreational cannabis outside work hours got the green light from California lawmakers on Tuesday, reported ABC News.
Evogene Q2 Revenue Grows 131% YoY, Here Is What You Need To Know
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) Q2 2022 revenue was $312,000, an increase of 131% compared to $135,000 in the same period the previous year.
Adastra Steps Into Magic Mushrooms! Gets Dealer’s License For Psilocybin And Psilocin
Adastra Holdings Ltd. (OTCPK:XTXXF) (CSE:XTRX) (FRA:D2EP) has received its Controlled Drug and Substances Dealer's License on August 24, 2022. This license allows Adastra to process psilocybin and psilocin, the active compounds derived from psychedelic mushrooms.
Lantern Bolsters Board With Columbia Care VP, Verano Taps M&A Pro, And Other Key Exec Moves
Top CEOs, investors and leaders in the cannabis industry will soon convene at the Benzinga Cannabis Capital Conference on Sept. 13-14 in Chicago.
PharmaCielo Q2 Revenue Soars 375% YoY, Raises Additional $4.6M In Oversubscribed Debenture Financing
PharmaCielo Ltd. (OTCQX: PCLOF) (TSXV:PCLO) Q2 2022 revenue was CA$2.1 million, a 375% increase compared to CA$446,000 in Q2 2021.